Holen Sie sich die Stockscreener-App
76.19
1.59%
1.19
Handel nachbörslich:
76.21
0.02
+0.03%
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Haemonetics (HAE) Joins Russell Indexes As Investors Ask If The Stock Is Still Undervalued - simplywall.st
HAE stock holds steady as investors track Haemonetics' product mix - ad-hoc-news.de
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $79 - 富途牛牛
Haemonetics sets Aug. 6 call for Q1 2027 results - Stock Titan
Haemonetics (HAE) Analyst Adjusts Price Target Despite Neutral R - GuruFocus
Haemonetics Corp updates investors on blood management business. Operational focus supports long-ter - ad-hoc-news.de
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? - Yahoo Finance
Haemonetics Corporation's $210 Million Cash Flow: Is The Transition Working? - Smartkarma
Daily Brief Health Care: Bausch Health Companies, Biodexa Pharmaceuticals, Fortrea Holdings , Haemonetics Corp, Legend Biotech Corp and more - Smartkarma
Haemonetics Corp updates plasma strategy, shares tracked against U.S. medtech peers - Ad-hoc-news.de
Haemonetics’ Broad Russell Value Index Inclusion Might Change The Case For Investing In Haemonetics (HAE) - simplywall.st
HAE Reiterated by BTIG -- Price Target Maintained at $84 - GuruFocus
Haemonetics Corp (HAE) Stock Up 6.5% and Still Undervalued -- GF Score: 84/100 - GuruFocus
[Latest] Global Therapeutic Apheresis Market Size/Share Worth USD 8.94 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Haemonetics Corp (HAE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $85 - 富途牛牛
Quietly ambitious, Haemonetics NexSys PCS pushes plasma efficiency further - AD HOC NEWS
Why Haemonetics’ NexSys PCS quietly reshapes plasma collection on the clinic floor - AD HOC NEWS
Haemonetics Corp (HAE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Haemonetics Corp (HAE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Haemonetics Corp (HAE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Haemonetics Corp (HAE) Institutional Confidence - TradingKey
Haemonetics Corp (HAE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Haemonetics Corp (HAE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Haemonetics Corp (HAE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Haemonetics Corp (HAE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Loomis Sayles Small Cap Core Portfolio's Haemonetics Corp(HAE) Holding History - GuruFocus
HAE Reiterated by BTIG -- Price Target Maintained at $84.00 - GuruFocus
Haemonetics Corp (HAE) Shares Fall 3.2% -- What GF Score of 77 T - GuruFocus
HAE: Upcoming Virtual Meeting Scheduled for June 24 - GuruFocus
HAE Maintained by Mizuho -- Price Target Raised to $85.00 - GuruFocus
Mizuho raises Haemonetics stock price target to $85 on plasma demand - Investing.com UK
HAE SEC FilingsHaemonetics Corp Mass 10-K, 10-Q, 8-K Forms - Stock Titan
Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices? - simplywall.st
HAEMONETICS CORP ($HAE) President and CEO 2026 Pay Revealed - Quiver Quantitative
[ARS] HAEMONETICS CORP SEC Filing - Stock Titan
Executive pay and equity plans in Haemonetics (NYSE: HAE) 2026 proxy filing - Stock Titan
A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment - Yahoo Finance
A Look at Haemonetics Corp (HAE) After 5.0% Gain -- GF Value $84 - GuruFocus
Haemonetics (NYSE: HAE) VP settles RSU taxes with 259 withheld shares - Stock Titan
Haemonetics (HAE) SVP has 313 shares withheld for RSU tax obligations - Stock Titan
Haemonetics Corp at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Haemonetics Corp stock (US4041191090): solid growth story in blood management and plasma technology - Ad-hoc-news.de
Is Haemonetics (HAE) Stock Price Reflecting Its Recent 29% Monthly Surge Accurately - simplywall.st
Haemonetics Corp stock (US4041191090): segment restructuring shifts focus to Apheresis and MedSurg - Ad-hoc-news.de
Haemonetics Restructures Business Segments for Enhanced Efficien - GuruFocus
Haemonetics Updates Financial Reporting Segments, Combines Plasma and Blood Center Into Apheresis, Renames Hospital to MedSurg 1 - Minichart
Haemonetics restructures reporting segments from three to two - Investing.com
Haemonetics updates reporting structure, combines Plasma and Blood Center into Apheresis - TradingView
Haemonetics (NYSE: HAE) consolidates business into new Apheresis and MedSurg segments - Stock Titan
Haemonetics Updates Financial Reporting Segments - PR Newswire
Haemonetics Corp (HAE) Shares Surge 6.0% -- What GF Score of 79 Tells Investors - GuruFocus
Haemonetics earnings ahead: Can vascular closure rebound? - Investing.com
Haemonetics stock falls from recent highs amid weekly seller pressure and overbought signals - Traders Union
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference - PR Newswire
Goldman Sachs healthcare forum hosts Haemonetics CEO fireside chat - Stock Titan
Haemonetics Corp stock (US4041191090): shares trade lower after recent pullback on NYSE - AD HOC NEWS
HAEHaemonetics Corp Stock Price and Quote - Finviz
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $70 - 富途牛牛
HAE Maintained by Citigroup -- Price Target Raised to $70 - GuruFocus
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):